Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash & Equivalents for 10 consecutive years, with $52.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 9.93% to $52.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.7 million, a 9.93% increase, with the full-year FY2024 number at $89.6 million, up 48.32% from a year prior.
  • Cash & Equivalents was $52.7 million for Q3 2025 at Rhythm Pharmaceuticals, down from $106.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $185.4 million in Q3 2022 to a low of $48.0 million in Q3 2024.
  • A 5-year average of $93.3 million and a median of $88.6 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 114.86% in 2022, then tumbled 64.99% in 2023.
  • Rhythm Pharmaceuticals' Cash & Equivalents stood at $59.6 million in 2021, then skyrocketed by 114.86% to $128.0 million in 2022, then plummeted by 52.81% to $60.4 million in 2023, then skyrocketed by 48.32% to $89.6 million in 2024, then tumbled by 41.13% to $52.7 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cash & Equivalents are $52.7 million (Q3 2025), $106.6 million (Q1 2025), and $89.6 million (Q4 2024).